ALEXION ACCESS FOUNDATION
https://N/A
$101K
Total Assets (2024)
$144.8M
Total Giving (2024)
10
Grants on File (2023–2024)
$29.0M
Avg Grant Size
Focus Areas
Application Information
Accepts Unsolicited Proposals
Unknown
Contact Person
ALEXION ACCESS FOUNDATION
Phone
4752302596
Deadlines
NONE
How to Apply
APPLICATION FORM
Restrictions
ELIGIBLE PARTICIPANTS IN THE ALEXION ACCESS FOUNDATION PROGRAM ARE GENERALLY REQUIRED TO MEET, AMONG OTHER THINGS, MEDICAL, INSURANCE AND FINANCIAL CRITERIA TO BE ELIGIBLE FOR SUPPORT.
Financial Trends
Giving Over Time
Total Assets Over Time
View financial data as table
| Year | Total Giving | Total Assets | Revenue | Grants |
|---|---|---|---|---|
| 2023 | $110.2M | $101K | $110.2M | 5 |
| 2024 | $144.8M | $0 | $144.8M | 5 |
Grant Size Distribution
Min: $3.1M
Median: $24.1M
Avg: $25.5M
Max: $70.4M
Geographic Distribution
Key Personnel
| Name | Title | Compensation |
|---|---|---|
| ERIC ROGERS | PRESIDENT/DIRECTOR | — |
| TAMAR THOMPSON | DIRECTOR | — |
| ISABEL FIRMINO | DIRECTOR | — |
Grants Awarded (10 total)
| Recipient | Location | Amount | Purpose | Year |
|---|---|---|---|---|
| VIALS OF STRENSIQ WERE DISTRIBUTED | NEW HAVEN, CT | $70,366,296 | PROVIDE ALEXION PRODUCT AT NO CHARGE TO ELIGIBLE PATIENTS WHO ARE UNABLE TO AFFORD THE PRESCRIBED PRODUCT | 2024 |
| VIALS OF ULTOMIRIS WERE DISTRIBUTED | NEW HAVEN, CT | $45,030,794 | PROVIDE ALEXION PRODUCT AT NO CHARGE TO ELIGIBLE PATIENTS WHO ARE UNABLE TO AFFORD THE PRESCRIBED PRODUCT | 2024 |
| VIALS OF STRENSIQ WERE DISTRIBUTED | NEW HAVEN, CT | $36,694,944 | PROVIDE ALEXION PRODUCT AT NO CHARGE TO ELIGIBLE PATIENTS WHO ARE UNABLE TO AFFORD THE PRESCRIBED PRODUCT | 2023 |
| VIALS OF SOLIRIS WERE DISTRIBUTED T | NEW HAVEN, CT | $36,687,708 | PROVIDE ALEXION PRODUCT AT NO CHARGE TO ELIGIBLE PATIENTS WHO ARE UNABLE TO AFFORD THE PRESCRIBED PRODUCT | 2023 |
| VIALS OF ULTOMIRIS WERE DISTRIBUTED | NEW HAVEN, CT | $25,637,347 | PROVIDE ALEXION PRODUCT AT NO CHARGE TO ELIGIBLE PATIENTS WHO ARE UNABLE TO AFFORD THE PRESCRIBED PRODUCT | 2023 |
| VIALS OF SOLIRIS WERE DISTRIBUTED T | NEW HAVEN, CT | $22,621,764 | PROVIDE ALEXION PRODUCT AT NO CHARGE TO ELIGIBLE PATIENTS WHO ARE UNABLE TO AFFORD THE PRESCRIBED PRODUCT | 2024 |
| VIALS OF KOSELUGO WERE DISTRIBUTED | NEW HAVEN, CT | $7,299,824 | PROVIDE ALEXION PRODUCT AT NO CHARGE TO ELIGIBLE PATIENTS WHO ARE UNABLE TO AFFORD THE PRESCRIBED PRODUCT | 2023 |
| VIALS OF KANUMA WERE DISTRIBUTED TO | NEW HAVEN, CT | $3,920,640 | PROVIDE ALEXION PRODUCT AT NO CHARGE TO ELIGIBLE PATIENTS WHO ARE UNABLE TO AFFORD THE PRESCRIBED PRODUCT | 2023 |
| VIALS OF KOSELUGO WERE DISTRIBUTED | NEW HAVEN, CT | $3,644,245 | PROVIDE ALEXION PRODUCT AT NO CHARGE TO ELIGIBLE PATIENTS WHO ARE UNABLE TO AFFORD THE PRESCRIBED PRODUCT | 2024 |
| VIALS OF KANUMA WERE DISTRIBUTED TO | NEW HAVEN, CT | $3,093,630 | PROVIDE ALEXION PRODUCT AT NO CHARGE TO ELIGIBLE PATIENTS WHO ARE UNABLE TO AFFORD THE PRESCRIBED PRODUCT | 2024 |